Thromb Haemost 2008; 99(05): 799-800
DOI: 10.1160/TH08-04-0200
Editorial Focus
Schattauer GmbH

Propagating factor IX-producing hepatocytes for haemophilia B therapy

Frederick A. Ofosu
1   Canadian Blood Services and Department of Pathology & Molecular Medicine, McMaster University, Hamilton, Ontario, Canada
› Author Affiliations
Further Information

Publication History

Received 01 April 2008

Accepted 01 April 2008

Publication Date:
30 November 2017 (online)

 

 
  • References

  • 1 Roberts HR, Eberst ME. Current management of hemophilia B. Hematol/Oncol Clin North Am 1993; 7: 1269-1280.
  • 2 Nathwani AC, Davidoff AM, Tuddenham EG. Prospects for gene therapy of haemophilia. Haemophilia 2005; 10: 309-318.
  • 3 Wang L, Takabe K, Bidlingmaier SM. et al. Sustained correction of bleeding disorder in hemophilia B mice by gene therapy. Proc Natl Acad Sci USA 1999; 96: 2906-3910.
  • 4 Kay MA, Rothenberg S, Landen CN. et al. In vivo gene therapy of hemophilia B: Sustained partial correction in factor IX deficient dogs. Science 1993; 262: 177-119.
  • 5 Herzog RW, Yang EY, Couto LB. et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated vira vector. Nat Med 1999; 5: 56-63.
  • 6 Park F, Ohashi K, Kay MA. Therapeutic levels of human factor VIII and IX using HIV-1-based lentiviral vectors in mouse liver. Blood 2000; 96: 1173-1176.
  • 7 Manno CS, Chew AJ, Hutchison S. et al. AAV-mediated factor IX gene transfer to skeletal muscles in patients with severe hemophilia B. Blood 2003; 101: 2963-2972.
  • 8 Manno CS, Pierce GF, Arruda VR. et al. Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by host immune response. Nat Med 2006; 12: 342-347.
  • 9 Nathwani AC, Davidoff A, Hanawa H. et al. Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing human factor IX cDNA. Blood 2001; 97: 1258-1265.
  • 10 Ashrani AA, Reding MT, Shet A. et al. Successful liver transplantation in a patient with severe haemophilia A and a high-titre inhibitor. Haemophilia 2004; 10: 735-737.
  • 11 Wilde J, Teixeira P, Bramhall SR. et al. Liver transplantation in haemophilia. Br J Haematol 2002; 117: 952-956.
  • 12 Gordon FH, Mistry PK, Sabin CA. et al. Outcome of orthotopic liver transplantation in patients with haemophilia. Gut 1998; 42: 755-749.
  • 13 Dhawan A, Mitry RR, Hughes RD. et al. Hepatocyte transplantation for inherited factor VII deficiency. Transplantation 2004; 78: 1812-1814.
  • 14 Ohashi K, Waugh JM, Dake MD. et al. Liver tissue engineering at extra hepatic sites in mice as a potential new therapy for genetic liver diseases. Hepatology 2005; 41: 132-140.
  • 15 Tatsumi K, Ohashi K, Miho K. et al. Successful in vivo propagation of factor IX-producing hepatocytes in mice: potential cell therapy in haemophilia B. Thromb Haemost 2008; 99: 883-891.